Investors & News / Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com — Read more about Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com — Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer Read more about Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy Read more about Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022 Read more about Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022 Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022 Read more about Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline Read more about Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα Read more about Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan Read more about Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update Read more about Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update Pagination First page « First Previous page ‹ Previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page Next › Last page Last » Subscribe to Receive Email Alerts Sign up to receive email alerts whenever Exelixis, Inc. posts new information to the site. Just enter your email address and click Submit. Required fields denoted by an asterisk (). Alert type Exelixis SEC Alert Exelixis End-of-Day SEC Alert Exelixis Calendar Alert Exelixis News Alert Exelixis Report Alert Email Leave this field blank Shareholder Tools Information Request Print Page RSS
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com — Read more about Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer Read more about Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy Read more about Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022 Read more about Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022 Read more about Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline Read more about Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα Read more about Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan Read more about Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update Read more about Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update